| Size | Price | |
|---|---|---|
| Other Sizes |
| Targets |
Purine nucleoside metabolism pathways; DNA synthesis. As a purine nucleoside analog, 1,3,5-Tri-O-benzoyl-alpha-D-ribofuranose serves as a precursor in the synthesis of nucleosides that disrupt nucleic acid synthesis. The compound targets rapidly dividing cells, particularly lymphoid malignancies. The benzoyl groups protect the hydroxyl groups during chemical synthesis.
|
|---|---|
| ln Vitro |
1,3,5-Tri-O-benzoyl-alpha-D-ribofuranose demonstrates activity as a purine nucleoside analog in cellular assays. Purine nucleoside analogs have broad-spectrum anticancer effects targeting indolent lymphoid malignancies. The compound is primarily used as a synthetic intermediate. Detailed IC50 values against specific cancer cell lines have not been disclosed.
|
| ln Vivo |
In vivo activity of 1,3,5-Tri-O-benzoyl-alpha-D-ribofuranose has not been extensively characterized. As a purine nucleoside analog precursor, it contributes to the synthesis of antileukemia drugs such as Clofarabine. The compound itself is not used directly in vivo; its biological activity is realized through the final nucleoside products.
|
| Enzyme Assay |
Not applicable for biological assays; the compound is a synthetic intermediate. For nucleoside synthesis, standard organic chemistry methods are used. The compound is characterized by HPLC (purity ≥98%), NMR, and mass spectrometry to confirm identity and purity. The benzoyl groups are removed during deprotection steps to yield the free ribofuranose for nucleoside synthesis.
|
| Cell Assay |
Cells are not typically treated directly with 1,3,5-Tri-O-benzoyl-alpha-D-ribofuranose. The compound is used in chemical synthesis of nucleosides and nucleoside analogs. The final deprotected products or synthesized nucleosides may be tested in cellular assays for anticancer activity.
|
| Animal Protocol |
In vivo animal studies for 1,3,5-Tri-O-benzoyl-alpha-D-ribofuranose have not been reported. The compound is primarily used as a synthetic building block. The antileukemia drug Clofarabine, which is synthesized using this compound, has well-established in vivo efficacy in animal models and clinical settings.
|
| ADME/Pharmacokinetics |
Pharmacokinetic data for 1,3,5-Tri-O-benzoyl-alpha-D-ribofuranose have not been published. The compound has a molecular weight of 462.45 and formula C26H22O8. The benzoyl groups may affect solubility and stability. In vivo PK parameters have not been characterized.
|
| Toxicity/Toxicokinetics |
Toxicology data for 1,3,5-Tri-O-benzoyl-alpha-D-ribofuranose have not been published. The compound is for research use only and not approved for human therapeutic applications. No systematic toxicological evaluation has been performed. Standard safety precautions for handling chemical intermediates should be observed.
|
| References | |
| Additional Infomation |
1,3,5-Tri-O-benzoyl-alpha-D-ribofuranose (CAS: 22224-41-5, molecular formula C26H22O8, molecular weight 462.45) is a purine nucleoside analog and synthetic intermediate. It is a reagent for nucleosides used in the synthesis of the antileukemia drug Clofarabine. It is not in clinical trials and has no regulatory approval. The compound is supplied as a research-grade intermediate for laboratory use only.
|
| Molecular Formula |
C26H22O8
|
|---|---|
| Molecular Weight |
462.45
|
| Exact Mass |
462.131
|
| CAS # |
22224-41-5
|
| PubChem CID |
11005061
|
| Appearance |
White to off-white solid powder
|
| Density |
1.4±0.1 g/cm3
|
| Boiling Point |
629.6±55.0 °C at 760 mmHg
|
| Melting Point |
125-129 °C(lit.)
|
| Flash Point |
213.0±25.0 °C
|
| Vapour Pressure |
0.0±1.9 mmHg at 25°C
|
| Index of Refraction |
1.633
|
| LogP |
6.12
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
10
|
| Heavy Atom Count |
34
|
| Complexity |
691
|
| Defined Atom Stereocenter Count |
4
|
| SMILES |
C1=CC=C(C=C1)C(=O)OC[C@@H]2[C@H]([C@H]([C@H](O2)OC(=O)C3=CC=CC=C3)O)OC(=O)C4=CC=CC=C4
|
| InChi Key |
HUHVPBKTTFVAQF-PIXQIBFHSA-N
|
| InChi Code |
InChI=1S/C26H22O8/c27-21-22(33-24(29)18-12-6-2-7-13-18)20(16-31-23(28)17-10-4-1-5-11-17)32-26(21)34-25(30)19-14-8-3-9-15-19/h1-15,20-22,26-27H,16H2/t20-,21-,22-,26-/m1/s1
|
| Chemical Name |
[(2R,3S,4R,5R)-3,5-dibenzoyloxy-4-hydroxyoxolan-2-yl]methyl benzoate
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 2.1624 mL | 10.8120 mL | 21.6240 mL | |
| 5 mM | 0.4325 mL | 2.1624 mL | 4.3248 mL | |
| 10 mM | 0.2162 mL | 1.0812 mL | 2.1624 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
